Tanvex BioPharma Completes Acquisition of Bora Biologics
Biologics and biosimilars CDMO, Tanvex, has successfully completed its acquisition of Bora Biologics, a subsidiary of Bora Pharmaceuticals. The companies will merge their biosimilar expertise and Tanvex’s FDA-licensed commercial-scale facility in San Diego with Bora Biologics' early-stage biologics CDMO capabilities in Taiwan to offer comprehensive, efficient end-to-end biologics solutions.
Following this acquisition, Tanvex's CDMO services will operate under the name Bora Biologics but continue to be owned by Tanvex. Stephen Lam, CEO of Tanvex, will lead the merged entity while Bobby Sheng, Bora Group Chairman, will Chair Tanvex.
Tanvex BioPharma, Inc. (“Tanvex”), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars products company, is pleased to announce the successful completion of its acquisition of Bora Biologics Co., Ltd. (“Bora Biologics”), a subsidiary of Bora Pharmaceuticals. Following this acquisition, Tanvex’s CDMO services will operate under the name Bora Biologics, continuing to be owned by Tanvex.
“The completion of this acquisition marks a pivotal moment for Tanvex and Bora Biologics,” said Stephen Lam, Chief Executive Officer of Tanvex. “We are adopting the name Bora Biologics to honor the legacy, reputation, and partnership power of a Bora brand, while seamlessly integrating its strengths with our commercialization success in the U.S. and our innovative vision and commitment to advancing biologics development. We believe that Bora Biologics will play a pivotal role in the future of biologics development.”
This acquisition merges Tanvex’s expertise in biosimilar development and commercialization at its FDA-licensed commercial-scale facility in San Diego with Bora’s extensive global early-stage biologics CDMO capabilities in Taiwan, leveraging a proven track record of over 100 successful cGMP manufacturing batches. This empowers the newly formed Bora Biologics to deliver agile, comprehensive end-to-end solutions that drive both time and cost efficiencies for biologics customers worldwide.
Stephen Lam will continue to lead the newly merged organization, ensuring a seamless integration of Bora’s robust operational resources and client-centric culture with Tanvex’s proven development and manufacturing capabilities. The collaboration aims to provide clients with early-stage biologics development capabilities in Taiwan, along with seamless technical transfer services to the late-stage and commercial biologics center in San Diego, which will provide a manufacturing platform with multiple 2000 L bioreactors.
Bobby Sheng, Chairman of the Bora Group, will become Chairman of Tanvex. Bora Biologics will collaborate closely with the Bora Group to provide its clients an end -to-end service through fill and finish capabilities in the U.S. This collaborative leadership will foster seamless integration and drive a culture of innovation and operational excellence across both regions.
“With this acquisition, we capitalize on evolving industry demands and provide our clients with unparalleled support and innovation in biologics development,” added Sheng.
The transition to Bora Biologics will not affect ongoing projects or operations, and clients can expect the same level of excellence and dedication they have come to rely on from Tanvex CDMO. All existing contracts and partnerships will be honored under the new brand.
As Bora Biologics, the organization will continue to build upon its established reputation for quality and excellence in manufacturing while expanding its capabilities to meet the needs of biopharma companies seeking efficient pathways to market.
As Bora Biologics, the organization remains steadfast in its mission to develop and manufacture with quality, innovation, and efficiency, empowering biopharma companies to bring life-saving therapies to market faster and more effectively.
The Tanvex biosimilar product line will continue to operate under the Tanvex brand, ensuring a seamless progression of planned and future commercialization efforts.
For more, please find the original story source here.